Dunn holds an MBA from Saint Joseph’s University, a BBA in Accounting from Pace University, and previously practiced as a Certified Public Accountant. He has led or played an integral role in more than 45 M&A, licensing and divestiture transactions valued at more than $12 billion. Dunn has more than 25 years of global experience in the life sciences industry, spanning large-cap, mid-cap specialty, and start-up companies. Prior to Patheon, he led corporate development and strategy activities through key phases of growth at NuPathe Inc (acquired by Teva), Inspire Pharmaceuticals (acquired by Merck) and Pfizer. Previously, he served as Vice President, Strategy and Corporate Development at Patheon, a leading biopharmaceutical contract manufacturing organization, up until Patheon’s acquisition by Thermo Fisher. Dunn was Senior Vice President, Corporate Development at Vivelix Pharmaceuticals, a clinical-stage biotechnology company. in Biology from Messiah College.īart Dunn joined Collegium Pharmaceutical in August 2019 as Executive Vice President, Strategy and Corporate Development. Throughout his career, he has been involved in the commercialization of over 35 products across more than 15 therapeutic areas and launched over 20 products. Director of Strategic Planning and Director of Cardiovascular Marketing. Regional Marketing Leader – Neuroscience, Executive Director Customer Marketing and Solutions, Sr. Primary Care Sales, Executive Director U.S.
Hospital and Oncology Sales and Commercial Operations, Vice President-U.S. Dreyer held various commercial leadership positions of increasing responsibility at Merck & Co, including Vice President-U.S. Prior to joining The Medicines Company, he was Vice President and Chief Marketing Officer-U.S.
Dreyer was Senior Vice President, Marketing and Commercial Operations for The Medicines Company.
He has over 25 years of commercial experience across sales, marketing, commercial operations and strategic planning, all within the biopharma industry. Dreyer joined Collegium in January 2018 as Senior Vice President of Sales, Marketing, Commercial Capabilities and Training. Scott Dreyer was appointed Executive Vice President and Chief Commercial Officer in July 2018. We are a team of doers - to support people with serious medical conditions, our healthcare professionals and our neighbors. We are a team of believers - in our products, values and impact. We are proud of our portfolio to support people living with pain, which includes internally developed and more recently acquired products, each of which represents meaningful innovation and, together, reflect our commitment to leadership in responsible pain management. Building a leading, diversified specialty pharmaceutical companyĬollegium Pharmaceutical is growing our portfolio of differentiated medications to responsibly treat serious medical conditions, including moderate-to-severe pain. That is why we are so passionate about the work we do to make a positive difference for people with serious medical conditions and our broader communities. Our team believes that people living with serious medical conditions deserve to enjoy their daily lives and spending time with the people around them. About us Inspired to make a positive difference in the lives of people living with serious medical conditions
0 kommentar(er)
